Guideline for PET/CT imaging of neuroendocrine neoplasms with Ga-68-DOTA-conjugated somatostatin receptor targeting peptides and F-18-DOPA

BOZKURT, MURAT; Virgolini, Irene; Balogova, Sona; Beheshti, Mohsen; Rubello, Domenico; Decristoforo, Clemens; Ambrosini, Valentina; Kjaer, Andreas; Delgado-Bolton, Roberto; Kunikowska, Jolanta; Oyen, Wim; Chiti, Arturo; Giammarile, Francesco; Fanti, Stefano

doi:10.1007/s00259-017-3728-y

Guideline for PET/CT imaging of neuroendocrine neoplasms with Ga-68-DOTA-conjugated somatostatin receptor targeting peptides and F-18-DOPA

Copy For Citation

BOZKURT M. F., Virgolini I., Balogova S., Beheshti M., Rubello D., Decristoforo C., ...More

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.44, no.9, pp.1588-1601, 2017 (SCI-Expanded)

Publication Type: Article / Article
Volume: 44 Issue: 9
Publication Date: 2017
Doi Number: 10.1007/s00259-017-3728-y
Journal Name: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.1588-1601
Hacettepe University Affiliated: Yes

Abstract

Purpose & Methods Neuroendocrine neoplasms are a heterogenous group of tumours, for which nuclear medicine plays an important role in the diagnostic work-up as well as in the targeted therapeutic options. This guideline is aimed to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of somatostatin receptor (SSTR) PET/CT imaging using Ga-68-DOTA-conjugated peptides, as well as F-18-DOPA imaging for various neuroendocrine neoplasms. Results & Conclusion The previous procedural guideline by EANM regarding the use PET/CT tumour imaging with Ga-68-conjugated peptides has been revised and updated with the relevant and recent literature in the field with contribution of distinguished experts.